Thromb Haemost 2019; 119(01): 140-148
DOI: 10.1055/s-0038-1676522
Stroke, Systemic or Venous Thromboembolism
Georg Thieme Verlag KG Stuttgart · New York

The Prognostic Value of Renal Function in Acute Pulmonary Embolism—A Multi-Centre Cohort Study

Maciej Kostrubiec
1   Department of Internal Medicine & Cardiology, Medical University of Warsaw, Warsaw, Poland
,
Magdalena Pływaczewska
1   Department of Internal Medicine & Cardiology, Medical University of Warsaw, Warsaw, Poland
,
David Jiménez
2   Respiratory Department and Medicine Department, Ramón y Cajal Hospital, IRYCIS and Alcalá de Henares University, Madrid, Spain
,
Mareike Lankeit
3   Clinic of Cardiology and Pneumology, Heart Center, University Medical Center Göttingen, Germany
4   Department of Internal Medicine and Cardiology, Campus Virchow Klinikum (CVK), Charité – University Medicine Berlin, Berlin, Germany
5   Center for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany
,
Michał Ciurzynski
1   Department of Internal Medicine & Cardiology, Medical University of Warsaw, Warsaw, Poland
,
Stavros Konstantinides
5   Center for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany
,
Piotr Pruszczyk
1   Department of Internal Medicine & Cardiology, Medical University of Warsaw, Warsaw, Poland
› Author Affiliations
Further Information

Publication History

09 August 2018

25 October 2018

Publication Date:
31 December 2018 (online)

Abstract

Background Haemodynamic alterations caused by acute pulmonary embolism (PE) may affect multi-organ function including kidneys. This multi-centre, multinational cohort study aimed to validate the prognostic significance of estimated glomerular filtration rate (eGFR) and its potential additive value to the current PE risk assessment algorithms.

Methods The post hoc analysis of pooled prospective cohort studies: 2,845 consecutive patients (1,424 M/1,421 F, 66 ± 17 years) with confirmed acute PE and followed up for 180 days. We tested prognostic value of pre-specified eGFR level ≤60 mL/min/1.73 m2 calculated on admission according to the Modification of Diet in Renal Disease study equation. The primary outcome was all-cause 30-day mortality; the secondary outcomes were PE-related mortality, 180-day all-cause mortality, bleeding and composite outcome (PE-related death, thrombolysis or embolectomy).

Results Two hundred and twenty-three patients (8%; 95% confidence interval [CI]: 7–9%) died within the first 30 days after the diagnosis. The eGFR on admission was significantly lower in non-survivors than in survivors (64 ± 34 vs. 75 ± 3 mL/min/1.73 m2, p < 0.0001). Independent predictors for a fatal outcome included: cancer, systolic blood pressure, older age, hypoxia, eGFR, heart rate and coronary artery disease. The eGFR of ≤60 mL/min/1.73 m2 independently predicted all-cause mortality (hazard ratio: 2.3; 95% CI: 1.7–3.0, p < 0.0001), PE-related outcome and clinically relevant bleedings (odds ratio: 0.90 per 10 mL/min/1.73 m2, 95% CI: 0.85–0.95, p = 0.0002). The eGFR assessment significantly improved prognostic models proposed by European guidelines with net re-classification improvement of 0.42 (p < 0.0001).

Conclusion The eGFR of ≤60 mL/min/1.73 m2 not only independently predicted higher 30- and 180-day all-cause mortality and bleeding events, but when added to the current European Society of Cardiology risk stratification algorithm improved identification of both low- and high-risk patients. Therefore, eGFR calculation should be implemented in the risk assessment of acute PE.

Supplementary Material

 
  • References

  • 1 Konstantinides SV, Torbicki A, Agnelli G. , et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 (43) 3033-3069
  • 2 Jiménez D, Aujesky D, Moores L. , et al; RIETE Investigators. Simplification of the Pulmonary Embolism Severity Index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170 (15) 1383-1389
  • 3 Kostrubiec M, Pruszczyk P, Bochowicz A. , et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26 (20) 2166-2172
  • 4 Ronco C, McCullough P, Anker SD. , et al; Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010; 31 (06) 703-711
  • 5 Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121 (03) 877-905
  • 6 Kostrubiec M, Łabyk A, Pedowska-Włoszek J. , et al. Assessment of renal dysfunction improves troponin-based short-term prognosis in patients with acute symptomatic pulmonary embolism. J Thromb Haemost 2010; 8 (04) 651-658
  • 7 Lankeit M, Jiménez D, Kostrubiec M. , et al. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124 (24) 2716-2724
  • 8 Jaff MR, McMurtry MS, Archer SL. , et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123 (16) 1788-1830
  • 9 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. ; Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
  • 10 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
  • 11 Levey AS, Coresh J, Greene T. , et al; Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53 (04) 766-772
  • 12 Palevsky PM, Liu KD, Brophy PD. , et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 2013; 61 (05) 649-672
  • 13 Lankeit M, Jiménez D, Kostrubiec M. , et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; 43 (06) 1669-1677
  • 14 Becattini C, Agnelli G, Lankeit M. , et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respir J 2016; 48 (03) 780-786
  • 15 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353 (9162): 1386-1389
  • 16 Conget F, Otero R, Jiménez D. , et al. Short-term clinical outcome after acute symptomatic pulmonary embolism. Thromb Haemost 2008; 100 (05) 937-942
  • 17 Falgá C, Capdevila JA, Soler S. , et al; RIETE Investigators. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 2007; 98 (04) 771-776
  • 18 Zondag W, Mos IC, Creemers-Schild D. , et al; Hestia Study Investigators. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011; 9 (08) 1500-1507
  • 19 Mullens W, Abrahams Z, Francis GS. , et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53 (07) 589-596
  • 20 Xue JL, Daniels F, Star RA. , et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006; 17 (04) 1135-1142
  • 21 Kostrubiec M, Łabyk A, Pedowska-Włoszek J. , et al. Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR indicate acute kidney injury and predict prognosis of patients with acute pulmonary embolism. Heart 2012; 98 (16) 1221-1228
  • 22 Chang CH, Fu CM, Fan PC. , et al. Acute kidney injury in patients with pulmonary embolism: a population-based cohort study. Medicine (Baltimore) 2017; 96 (09) e5822
  • 23 Testani JM, Brisco MA, Chen J, McCauley BD, Parikh CR, Tang WH. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol 2013; 62 (06) 516-524
  • 24 Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J 2015; 36 (23) 1437-1444
  • 25 Sokolski M, Zymliński R, Biegus J. , et al. Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. Eur J Heart Fail 2017; 19 (06) 760-767
  • 26 Kostrubiec M, Łabyk A, Pedowska-Włoszek J. , et al. Rapid improvement of renal function in patients with acute pulmonary embolism indicates favorable short term prognosis. Thromb Res 2012; 130 (03) e37-e42